Healthcare Industry News: Iclusig
News Release - June 23, 2014
ARIAD Announces Three Key Appointments to Its Global Management TeamCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--ARIAD Pharmaceuticals, Inc. (ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug safety and pharmacovigilance.
- Timothy Maines, Vice President, Quality
- Yan Moore, M.D., Vice President, Medical Affairs
- Piet A.M Vervaet, M.D., Vice President, Drug Safety and Pharmacovigilance
Timothy Maines leads the global quality function and has put in place systems to ensure quality and compliance in clinical, manufacturing and laboratory good practices. Mr. Maines brings over twenty years of leadership experience in quality operations and strategy to ARIAD.
Prior to joining ARIAD, Mr. Maines served as vice president, quality at Omthera Pharmaceuticals, where he was responsible for quality and technical GXP operations. He previously was vice president, corporate quality assurance at MedImmune, LLC, where he oversaw the quality assurance operations team at six GMP manufacturing facilities. Mr. Maines also was vice president, quality at GTC Biotherapeutics.
Mr. Maines has a B.S. degree in biology and microbiology from Gannon University.
Yan Moore, M.D. leads global medical affairs and is responsible for investigator-sponsored clinical-research activities, publications, medical information, key therapeutic leader engagement, medical affairs planning for ARIAD’s pipeline of oncology products and in collaboration with others, for life-cycle management of Iclusig® (ponatinib) and strategic planning for its current and future clinical indications.
Prior to joining ARIAD, Dr. Moore served as associate vice president, global medical affairs at Sanofi, where he was responsible for global medical affairs, clinical development and business opportunities for the company’s gastrointestinal and other solid-tumor products. He previously was executive director, oncology clinical development at GlaxoSmithKline and the cetuximab development group director at Bristol-Myers Squibb (BMS). He also was gastrointestinal cancer development lead for the oncology portfolio. Before joining BMS, Dr. Moore headed the medical affairs group at GPC Biotech, Inc. and was the global medical director at GE Healthcare (Oncura, Inc.) for urology and genitourinary oncology products.
Dr. Moore earned B.S. and M.D. degrees from the Sackler School of Medicine in Tel Aviv, Israel. He completed his internship in internal medicine at the Edith Wolfson Medical Center and a residency program in obstetrics and gynecology. He received his M.B.A. from the LeBow College of Business at Drexel University in Philadelphia.
Piet A.M Vervaet, M.D. leads global safety and pharmacovigilance and is responsible for safety surveillance, risk identification and risk management for ARIAD’s marketed and pipeline of oncology products, as well as proper risk communications to patients, healthcare professionals and health authorities. He also oversees, in collaboration with others, regulatory compliance with safety legislation for the Company’s products.
Prior to joining ARIAD, Dr. Vervaet served as vice president, drug safety and pharmacovigilance at Onyx Pharmaceuticals, where he was responsible for the strategic leadership and oversight for the pharmacovigilance and drug-safety function and focused on proactive and timely risk-benefit assessments of clinical data to characterize the safety profiles of the company’s oncology portfolio. He previously held therapeutic-area safety leadership positions at AstraZeneca, where he oversaw the safety of products in various therapeutic areas, including oncology, infectious diseases, gastroenterology, and pulmonology. Before joining AstraZeneca Dr. Vervaet held drug-safety positions in the U.S. and Europe at Johnson and Johnson.
Dr. Vervaet earned his B.S. and M.D. degrees from the University of Ghent in Belgium and completed residency programs at St. Elisabeth Hospital in Sijsele/Damme (Belgium).
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
This press release contains “forward-looking statements” including, but not limited to, statements regarding the progress and results of the clinical development, risk identification and risk management, regulatory processes, commercialization efforts or commercial potential of ARIAD’s pipeline and marketed products. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, preclinical data and early-stage clinical data that may not be replicated in later-stage clinical studies, the costs associated with our research, development, manufacturing and other activities, the conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Source: ARIAD Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.